PLAQUE PSORIASIS/PSORIATIC ARTHRITIS
CURRENTLY ENROLLING TRIALS
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to- Severe Plaque Psoriasis
Open for participants ages 18 to 75 with a diagnosis of plaque psoriasis for at least 6 months.
​
Requirements:
-
Moderate to severe plaque psoriasis
-
Candidate for systemic therapy
-
BMI less than or equal to 40
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Open for participants age ≥ 18 with a documented diagnosis of stable psoriatic arthritis for at least 6 months.
​
Requirements:
-
Diagnosis of active plaque psoriasis, with at least 1 psoriatic plaque of ≥ 2 cm diameter
-
≥ 3 tender and ≥ 3 swollen joints
-
Prior exposure to anti-tumor necrosis factor (anti-TNF) agent(s) for treatment of plaque psoriasis or psoriatic arthritis
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
UPCOMING CLINICAL TRIALS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants with Plaque Psoriasis in a Community Setting (Artistyk)
Open for participants age ≥ 18 with a diagnosis of stable plaque psoriasis for at least 6 months.
​
Requirements:
-
Moderate to severe plaque psoriasis
-
Candidate for systemic therapy
-
Plaque Psoriasis affecting ≥ 3% Body Surface Area (BSA), or at least 5 hand prints (1 hand print = 1%)
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
Don't qualify for any of our trials?
We begin new trials often. If you do not qualify for our current studies, please leave your information, and we'll keep you updated of any upcoming trials that may be right for you.